“The Oncologist” email appeared in my in-box
this morning:
Academia-Pharma Intersect: Hematologic Malignancies
Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents
Bruce D. Cheson, Sari Heitner Enschede, Elisa Cerri, Monali Desai, Jalaja Potluri, Nicole Lamanna, Constantine Tam
Tumor lysis syndrome is an uncommon but potentially life-threatening complication associated with the treatment of some cancers. In this review, prevention strategies and management of patients with chronic lymphocytic leukemia who develop tumor lysis syndrome are described.
Breast Cancer
Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System
Mariana Chavez-MacGregor, Elizabeth A. Mittendorf, Christina A. Clarke, Daphne Y. Lichtensztajn, Kelly K. Hunt, Sharon H. Giordano
The American Joint Committee on Cancer (AJCC) breast cancer staging system provides important prognostic information. The recently published eighth edition incorporates biological markers and recommends the use of a complex prognostic stage. In this study, the relationship between stage, breast cancer subtype, grade, and outcome in a large population-based cohort is assessed, and a risk score system incorporating tumor characteristic to the AJCC anatomic staging system is evaluated.
Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis
Miguel Martín, José I. Chacón, Antonio Antón, Arrate Plazaola, Elena García-Martínez, Miguel A. Seguí, Pedro Sánchez-Rovira, José Palacios, Lourdes Calvo, Carmen Esteban, Enrique Espinosa, Agusti Barnadas, Norberto Batista, Angel Guerrero, Montserrat Muñoz, Estefania Romio, César Rodríguez-Martín, Rosalía Caballero, María I. Casas, Federico Rojo, Eva Carrasco, Silvia Antolín
The NABRAX study was designed to evaluate the antitumor activity and safety of single-agent weekly nab-paclitaxel as neoadjuvant treatment of estrogen receptor-positive/HER2-negative breast cancer patients. This article reports on the trial and efforts to define the role of this drug and biomarkers of activity in this particular subtype of breast cancer.
Adipose-Derived Fatty Acid-Binding Proteins Plasma Concentrations Are Increased in Breast Cancer Patients
Sandra Guaita-Esteruelas, Paula Saavedra-García, Alba Bosquet, Joan Borràs, Josefa Girona, Kepa Amiliano, Marta Rodríguez-Balada, Mercedes Heras, Luís Masana, Josep Gumà
Circulating FABP4 and FABP5 may be a biomarker for breast cancer. This article focuses on the association of FABP4 and FABP5 plasma levels with the presence of breast cancer.
Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers
Xia Liu, Julia Y.S. Tsang, Thazin Hlaing, Jintao Hu, Yun-Bi Ni, Siu Ki Chan, Sai Yin Cheung, Gary M. Tse
Tumor infiltrating lymphocytes are associated with good clinical outcome in many types of cancer, including breast cancer. Tertiary lymphoid structures are associated with anti-tumor immune responses and prolonged patient survival. This study analyzed characteristics of tertiary lymphoid structures and their prognostic value related to different invasive breast cancer molecular subgroups.
Cancer Diagnostics and Molecular Pathology
Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non-Small Cell Lung Cancer
Yanxi Han, Rui Zhang, Guigao Lin, Kuo Zhang, Jiehong Xie, Jinming Li
Advancements in molecular diagnosis have revolutionized traditional diagnosis and therapeutic management of non-small cell lung cancer. This study focuses on the quality assessment of gene mutation reports, focusing on EGFR gene mutation testing and reporting performance of the NCCL.
Community Outreach
Predictors of Disruptions in Breast Cancer Care for Individuals with Schizophrenia
Kelly E. Irwin, Elyse R. Park, Jennifer A. Shin, Lauren E. Fields, Jamie M. Jacobs, Joseph A. Greer, John B. Taylor, Alphonse G. Taghian, Oliver Freudenreich, David P. Ryan, William F. Pirl
Disruptions in breast cancer are common for patients with schizophrenia and are associated with adverse outcomes. The aim of this study was to examine the proportion of patients with schizophrenia who received stage-appropriate breast cancer care, identify and categorize care processes that may interfere with receiving stage-appropriate care defined as care disruptions, and determine potentially modifiable predictors of care disruptions.
Geriatric Oncology
Are Disagreements in Caregiver and Patient Assessment of Patient Health Associated with Increased Caregiver Burden in Caregivers of Older Adults with Cancer?
Tina Hsu, Matthew Loscalzo, Rupal Ramani, Stephen Forman, Leslie Popplewell, Karen Clark, Vani Katheria, Rex Strowbridge, Redmond Rinehart, Dan Smith, Keith Matthews, Jeff Dillehunt, Tao Feng, David Smith, Canlan Sun, Arti Hurria
Cancer-related therapy is increasingly administered in the outpatient setting, resulting in increased dependence on caregivers suggest to provide physical and emotional support to patients. This article describes differences in patient versus caregiver assessments of patient health, considering caregiver perceptions of the patient's health and abilities compared to that reported by the patient.
Global Health and Cancer
Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China
Jianbin Li, Shusen Wang, Yongsheng Wang, Xiaojia Wang, Haibo Wang, Jifeng Feng, Qingyuan Zhang, Tao Sun, Quchang Ouyang, Yongmei Yin, Yinhua Liu, Cuizhi Geng, Min Yan, Zefei Jiang
The study of disparities in trastuzumab use has been complicated by the lack of population-based cohorts. Real-world research is lacking. This study used real-world data from a multicenter study in China to explore disparities in trastuzumab use and to investigate the survival effects of trastuzumab on early stage and metastatic breast cancer.
Regulatory Issues: EMA
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
Kyriaki Tzogani, Jorge Camarero Jiménez, Isabel Garcia, Arantxa Sancho-López, Marc Martin, Alexandre Moreau, Pierre Demolis, Tomas Salmonson, Jonas Bergh, Edward Laane, Heinz Ludwig, Christian Gisselbrecht, Francesco Pignatti
This article summarizes the scientific review of the application leading to regulatory approval of carfilzomib in combination with lenalidomide and dexamethasone in the European Union.
Regulatory Issues: FDA
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond
Lee Pai-Scherf, Gideon M. Blumenthal, Hongshan Li, Sriram Subramaniam, Pallavi S. Mishra-Kalyani, Kun He, Hong Zhao, Jingyu Yu, Mark Paciga, Kirsten B. Goldberg, Amy E. McKee, Patricia Keegan, Richard Pazdur
This FDA approval summary provides an update on approval of pembrolizumab for treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 as determined by an FDA-approved test. The results of KEYNOTE-010 and KEYNOTE-024 trials are presented.
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy
Vishal Bhatnagar, Nicole J. Gormley, Lola Luo, Yuan Li Shen, Rajeshwari Sridhara, Sriram Subramaniam, Guoxiang Shen, Lian Ma, Stacy Shord, Kirsten B. Goldberg, Ann T. Farrell, Amy E. McKee, Richard Pazdur
Multiple myeloma is mostly an incurable disease. The FDA granted daratumumab accelerated approval as monotherapy for patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or who are double refractory to a proteasome and an immunomodulatory agent. This article describes the FDA review of the strength of evidence for this application and its clinical implications for the multiple myeloma population.
Sarcomas
Soft Tissue Sarcomas of the Extremities: Surgical Margins Can Be Close as Long as the Resected Tumor Has No Ink on It
Kamran Harati, Ole Goertz, Andreas Pieper, Adrien Daigeler, Hamid Joneidi-Jafari, Hiltrud Niggemann, Ingo Stricker, Marcus Lehnhardt
Soft tissue sarcomas (STS) are a heterogeneous group of rare mesenchymal tumors, accounting for approximately 1% of all adult malignancies. About 60% of all STS arise in the extremities. This article reports on the clinical behavior of extremity STS and prognostic indicators of survival.
Symptom Management and Supportive Care
Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial
Se-Il Go, Dong-Hoe Koo, Seung Tae Kim, Haa-Na Song, Rock Bum Kim, Joung-Soon Jang, Sung Yong Oh, Kyung Hee Lee, Soon Il Lee, Seong-Geun Kim, Lee Chun Park, Sang-Cheol Lee, Byeong-Bae Park, Jun Ho Ji, Seong Yoon Yi, Yun-Gyoo Lee, Jina Yun, Eduardo Bruera, In Gyu Hwang, Jung Hun Kang
Dexamethasone is an established agent for the prevention of chemotherapy-induced nausea/vomiting; however, even a short course of dexamethasone can cause many adverse effects, such as insomnia, indigestion, weight gain, acne, and hiccupping. Although often regarded trivial, persistent hiccups can cause depression, insomnia, and malnutrition. The objective of this study was to determine whether the rotation of corticosteroids affects the incidence and intensity of dexamethasone-induced hiccup without compromising the antiemetic efficacy.
Development of Palliative Care in China: A Tale of Three Cities
Zhenyu Yin, Jinxiang Li, Ke Ma, Xiaohong Ning, Huiping Chen, Haiyan Fu, Haibo Zhang, Chun Wang, Eduardo Bruera, David Hui
Although the most populous country in the world, China has limited palliative care programs. This article presents examples of three palliative care programs in China and encourages the program development in other Chinese hospitals.
Advance Directives, Hospitalization, and Survival Among Advanced Cancer Patients with Delirium Presenting to the Emergency Department: A Prospective Study
Ahmed F. Elsayem, Eduardo Bruera, Alan Valentine, Carla L. Warneke Geri L. Wood, Sai-Ching J. Yeung, Valda D. Page, Julio Silvestre, Patricia A. Brock, Knox H. Todd
Delirium is a devastating condition for a patient with advanced cancer. Early diagnosis in the emergency department should improve management of this life-threatening condition. This article presents results of a prospective study of patients with advanced cancer who presented to the emergency department at MD Anderson Cancer Center and were assessed for delirium.
Letters to the Editor
Regarding “Survival Outcomes in Asymptomatic Patients with Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging”
Fergus Macbeth, Tom Treasure
This Letter to the Editor questions the benefits of a recently reported CT-PET scan screening policy in terms of improving survival in patients with colorectal cancer.
In Reply
Khurum Khan, David Cunningham, Katharine Aitken, Sheela Rao
This Letter to the Editor acknowledges the limitations of a cohort observational study compared with a randomized clinical trial and defends the results of a recent study.>
No comments:
Post a Comment